Who are albuterol plus tiotropium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albuterol-plus-tiotropium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

albuterol plus tiotropium — Competitive Intelligence Brief

albuterol plus tiotropium (albuterol plus tiotropium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination bronchodilator (SABA + LAMA). Area: Respiratory/Pulmonology.

marketed Combination bronchodilator (SABA + LAMA) Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

albuterol plus tiotropium (albuterol plus tiotropium) — IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. Albuterol and tiotropium work together as a combination bronchodilator therapy: albuterol provides rapid short-acting relief by stimulating beta-2 adrenergic receptors, while tiotropium provides sustained long-acting bronchodilation by blocking muscarinic M3 receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
albuterol plus tiotropium TARGET	albuterol plus tiotropium	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	marketed	Combination bronchodilator (SABA + LAMA)	Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination bronchodilator (SABA + LAMA) class)

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). albuterol plus tiotropium — Competitive Intelligence Brief. https://druglandscape.com/ci/albuterol-plus-tiotropium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab